Drug Patents owned by Upsher Smith Labs

1. List of Qudexy Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10363224 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(9 years from now)

US8652527 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(9 years from now)

US8889190 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(9 years from now)

US9555005 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(9 years from now)

US9101545 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(9 years from now)

Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 11 March, 2014

Treatment: Treatment of seizures

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of QUDEXY XR before it's patent expiration?
More Information on Dosage

QUDEXY XR family patents

12

United States

3

Korea, Republic of

1

Brazil

1

Canada

1

Israel

1

European Union

2. List of Tosymra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8440631 UPSHER SMITH LABS Compositions for drug administration
May, 2026

(2 years from now)

US8268791 UPSHER SMITH LABS Alkylglycoside compositions for drug administration
May, 2026

(2 years from now)

US9283280 UPSHER SMITH LABS Compositions for drug administration
May, 2026

(2 years from now)

US11337962 UPSHER SMITH LABS Formulations comprising triptan compounds
Jun, 2030

(7 years from now)

US10603305 UPSHER SMITH LABS Formulations comprising triptan compounds
Jun, 2030

(7 years from now)

US9974770 UPSHER SMITH LABS Formulations comprising triptan compounds
Jun, 2030

(7 years from now)

US9610280 UPSHER SMITH LABS Formulations comprising triptan compounds
Jun, 2030

(7 years from now)

US9211282 UPSHER SMITH LABS Formulations comprising triptan compounds
Jul, 2031

(8 years from now)

Drugs and Companies using SUMATRIPTAN ingredient

Market Authorisation Date: 25 January, 2019

Treatment: Acute treatment of migraine

Dosage: SPRAY;NASAL

More Information on Dosage

TOSYMRA family patents

56

United States

7

European Union

5

Japan

5

Australia

4

Canada

4

Korea, Republic of

4

China

4

Russia

3

United Kingdom

3

Brazil

3

Spain

2

India

2

Denmark

2

Mexico

2

New Zealand

1

Hong Kong

1

Germany

1

Morocco

IB

1

IB

EA

1

EA

1

South Africa

1

Singapore

1

Israel

3. List of Vogelxo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295675 UPSHER SMITH LABS Testosterone gel compositions and related methods
Feb, 2034

(10 years from now)

US8785426 UPSHER SMITH LABS Testosterone gel compositions and related methods
Feb, 2034

(10 years from now)

US9662340 UPSHER SMITH LABS Testosterone gel compositions and related methods
Feb, 2034

(10 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 04 June, 2014

Treatment: Method for transdermal delivery of testosterone

Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL

More Information on Dosage

VOGELXO family patents

5

United States

1

Australia

1

Hong Kong

1

South Africa

1

Canada

1

Singapore

1

European Union

4. List of Zembrace Symtouch drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11364224 UPSHER SMITH LABS Pharmaceutical composition for treating migraine
Jan, 2036

(12 years from now)

US10537554 UPSHER SMITH LABS Pharmaceutical composition for treating migraine
Jan, 2036

(12 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 28 January, 2016

Treatment: Treatment of migraine

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

ZEMBRACE SYMTOUCH family patents

4

United States

1

Brazil

1

India

1

Canada

1

China

1

Mexico

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic